Citations

Clear

361 citation(s) found for "Bauer, M".

A Randomized Clinical Trial of St. John's Wort for Smoking Cessation
Sood, Amit , Ebbert, Jon O. , Prasad, Kavita , Croghan, Ivana T. , Bauer, Brent A. , Schroeder, Darrell R. , Schroeder, Darrell

Mayo Clinic

The Journal of Alternative and Complementary Medicine | June 30, 2010 | Volume: 16 | Issue: 7 | Pages: 761-767

10.1089/acm.2009.0445 | PMID 20590478 Get It

Dietary Supplement S -Adenosyl- l -Methionine (AdoMet) Effects on Plasma Homocysteine Levels in Healthy Human Subjects: A Double-Blind, Placebo-Controlled, Ra
Bauer, Brent A. , Loehrer, Laura L., Cha, Stephen S., Mandrekar, Jayawant N. , Sood, Amit , Wahner‐Roedler, Dietlind L. , Thompson, Michael A. , Cha, Stephen S.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | May 7, 2009 | Volume: 15 | Issue: 5 | Pages: 523-529

10.1089/acm.2008.0402 | PMID 19422296 Get It

CYTOTOXIC PROPERTIES OF DIOSPYROS SEYCHELLARUM EXTRACT
Buenz, Eric J. , Bauer, Brent A. , Motley, Timothy J., Limburg, Paul J.

Mayo Clinic

The Journal of Toxicological Sciences | January 17, 2008 | Volume: 32 | Issue: 5 | Pages: 487-493

10.2131/jts.32.487 | PMID 18198480 Get It

p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion
Tsui, Lisa, Camrud, Allan R., Mondesire, Jean, Carlson, Paula, Zayek, Nathalie, Camrud, Ladonna J., Donahue, Brian A., Lin, Andy, Frey, David , Rivkin, Marianne, Subramanian, Ajit, Falotico, Robert, Gyuris, Jenő, Schwartz, Robert S., McArthur, James G., Bauer, Scott R.

Mayo Clinic

Circulation Research | September 28, 2007 | Volume: 89 | Issue: 4 | Pages: 323-328

10.1161/hh1601.094482 | PMID 11509448 Get It

Inhibition of proliferative neointima formed by vascular smooth muscle cells is a potential target in preventing angioplasty-induced restenosis. We have created a potent antiproliferative by fusing the active regions of the p27 and p16 cell cycle inhibitors. Intravascular delivery of a replication-deficient adenoviral vector (AV) encoding this p27-p16 fusion protein, named W9, inhibited balloon injury–induced neointimal hyperplasia in rabbit carotid arteries. In a therapeutically more relevant model, AV-W9 was delivered to balloon-injured porcine coronary arteries in vivo using an infusion catheter. Of the three coronary arteries, two were injured with a 15-mm balloon catheter and either were left untreated or were treated with 10 12 viral particles of either AV-W9 or a control null virus. AV-W9 treatment significantly inhibited neointimal hyperplasia in this porcine arterial balloon injury model compared with untreated or control virus–treated vessels. The average intimal area of the AV-W9–treated group 10 days after balloon injury and treatment was 0.42±0.36 mm 2 , whereas the AV-null group demonstrated an intimal area of 0.70±0.52 mm 2 . At day 10 the average intimal thickness of the AV-W9–treated vessels was 9.1 μm (n=5, ×20 magnification) compared with 21.2 μm (n=5, ×20 magnification) in control virus–treated vessels. This trend was also observed at 28 days after balloon injury and gene transfer during which AV-W9–treated vessels demonstrated an average intimal thickness of 4.7 μm (n=8, ×20 magnification) compared with 13.3 μm (n=3, ×20 magnification) in control virus–treated vessels and 7.3 μm (n=5, ×20 magnification) in the sham-treated vessels. The AV-W9 treatment was safe and well tolerated. These data suggest that AV-W9 gene therapy may be useful in preventing angioplasty–induced intimal hyperplasia in the coronary artery.
A Critical Review of Complementary Therapies for Cancer-Related Fatigue
Sood, Amit , Barton, Debra L. , Bauer, Brent A. , Loprinzi, Charles L.

Mayo Clinic

Integrative Cancer Therapies | March 9, 2007 | Volume: 6 | Issue: 1 | Pages: 8-13

10.1177/1534735406298143 | PMID 17351022 Get It

Purpose: To review the available literature on the use of complementary and alternative medicine (CAM) treatments for cancer-related fatigue with an aim to develop directions for future research. Methods: PubMed, EMBASE, CINAHL, PsycINFO, and SPORTDiscus were searched for relevant studies. Original clinical trials reporting on the use of CAM treatments for cancer-related fatigue were abstracted and critically reviewed. Results: CAM interventions tested for cancer-related fatigue include acupuncture, aromatherapy, adenosine triphosphate infusions, energy conservation and activity management, healing touch, hypnosis, lectinstandardized mistletoe extract, levocarnitine, massage, mindfulness-based stress reduction, polarity therapy, relaxation, sleep promotion, support group, and Tibetan yoga. Several of these interventions seem promising in initial studies. Conclusion: Currently, insufficient data exist to recommend any specific CAM modality for cancer-related fatigue. Therefore, potentially effective CAM interventions ready for further study in large, randomized clinical trials (eg, acupuncture, massage, levocarnitine, and the use of mistletoe) should be pursued. Other interventions should be tested in well-designed feasibility and phase II trials.
Acquired Long QT Syndrome Secondary to Cesium Chloride Supplement
Vyas, Himeshkumar, Johnson, Katya, Houlihan, Robert J., Bauer, Brent A. , Ackerman, Michael J.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | January 9, 2007 | Volume: 12 | Issue: 10 | Pages: 1011-1014

10.1089/acm.2006.12.1011 | PMID 17212573 Get It

Efficacy of Complementary and Alternative Medicine Therapies in Relieving Cancer Pain: A Systematic Review
Bardia, Aditya , Barton, Debra L. , Bauer, Brent A. , Moynihan, Timothy J. , Prokop, Larry J.

Mayo Clinic

Journal of Clinical Oncology | November 30, 2006 | Volume: 24 | Issue: 34 | Pages: 5457-5464

10.1200/jco.2006.08.3725 | PMID 17135649 Get It

Purpose Despite widespread popular use of complementary and alternative medicine (CAM) therapies, a rigorous evidence base about their efficacy for cancer-related pain is lacking. This is a systematic review of randomized controlled trials (RCTs) evaluating CAM therapies for cancer-related pain. Methods RCTs using CAM interventions for cancer-related pain were abstracted using Medline, EMBASE, CINAHL, AMED, and Cochrane database. Results Eighteen trials were identified (eight poor, three intermediate, and seven high quality based on Jadad score), with a total of 1,499 patients. Median sample size was 53 patients, and median intervention duration was 45 days. All studies were from single institutions, four had sample size justification, and none reported any adverse effects. Seven trials reported significant benefit for the following CAM therapies: acupuncture (n = 1), support groups (n = 2), hypnosis (n = 1), relaxation/imagery (n = 2), and herbal supplement/HESA-A (n = 1, but study was of low quality without control data). Seven studies reported immediate postintervention or short-term benefit of the following CAM interventions: acupuncture (n = 2), music (n = 1), herbal supplement/Ai-Tong-Ping (n = 1), massage (n = 1), and healing touch (n = 2). Four studies reported no benefit of CAM interventions (music, n = 2; massage, n = 2) in reducing cancer pain compared with a control arm. Conclusion There is paucity of multi-institutional RCTs evaluating CAM interventions for cancer pain with adequate power, duration, and sham control. Hypnosis, imagery, support groups, acupuncture, and healing touch seem promising, particularly in the short term, but none can be recommended because of a paucity of rigorous trials. Future research should focus on methodologically strong RCTs to determine potential efficacy of these CAM interventions.
HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo
Narita, Keishi , Staub, Julie , Chien, Jeremy , Meyer, Kristy, Bauer, Maret, Friedl, Andreas , Ramakrishnan, Sundaram, Shridhar, Viji , Chien, Jeremey

Mayo Clinic

Cancer Research | June 15, 2006 | Volume: 66 | Issue: 12 | Pages: 6025-6032

10.1158/0008-5472.can-05-3582 | PMID 16778174 Get It

Abstract We previously identified HSulf-1 as a down-regulated gene in several tumor types including ovarian, breast, and hepatocellular carcinomas. Loss of HSulf-1, which selectively removes 6-O-sulfate from heparan sulfate, up-regulates heparin-binding growth factor signaling and confers resistance to chemotherapy-induced apoptosis. Here we report that HSulf-1 expression in MDA-MB-468 breast carcinoma clonal lines leads to reduced proliferation in vitro and reduced tumor burden in athymic nude mice in vivo. Additionally, xenografts derived from HSulf-1–expressing stable clones of carcinoma cells showed reduced vessel density, marked necrosis, and apoptosis, indicative of inhibition of angiogenesis. Consistent with this observation, HSulf-1–expressing clonal lines showed reduced staining with the endothelial marker CD31 in Matrigel plug assay, indicating that HSulf-1 expression inhibits angiogenesis. More importantly, HSulf-1 expression in the xenografts was associated with a reduced ability of vascular endothelial cell heparan sulfate to participate in a complex with fibroblast growth factor 2 (FGF-2) and its receptor tyrosine kinase FGF receptor 1c. In vitro, short hairpin RNA–mediated down-regulation of HSulf-1 in human umbilical vein endothelial cells (HUVEC) resulted in an increased proliferation mediated by heparan sulfate–dependent FGF-2, hepatocyte growth factor, and vascular endothelial growth factor 165 (VEGF165) but not by heparan sulfate–independent VEGF121. HSulf-1 down-regulation also enhanced downstream signaling through the extracellular signal–regulated kinase pathway compared with untreated cells. Consistent with the role of heparan sulfate glycosaminoglycan sulfation in VEGF-mediated signaling, treatment of HUVEC cells with chlorate, which inhibits heparan sulfate glycosaminoglycan sulfation and therefore mimics HSulf-1 overexpression, led to an attenuated VEGF-mediated signaling. Collectively, these observations provide the first evidence of a novel mechanism by which HSulf-1 modulates the function of heparan sulfate binding VEGF165 in proliferation and angiogenesis. (Cancer Res 2006; 66(12): 6025-32)
Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Karp, Judith E. , Passaniti, Antonino , Gojo, Ivana , Kaufmann, Scott H. , Bible, Keith C. , Garimella, Τushar , Greer, Jacqueline M., Briel, Janet, Gore, Steven D. , Tidwell, Michael L., Ross, Douglas D., Wright, John J., Bauer, Kenneth S., Smith, B. Douglas , Wright, John J., Colevas, Alexander Dimitrios , Kaufmann, Scott H

Mayo Clinic

Clinical Cancer Research | March 21, 2006 | Volume: 11 | Issue: 23 | Pages: 8403-8412

10.1158/1078-0432.ccr-05-1201 | PMID 16322302 Get It

Abstract Purpose: The serine/threonine kinase inhibitor flavopiridol targets multiple cyclin-dependent kinases, induces checkpoint arrest, and interrupts transcriptional elongation. We designed a phase I clinical trial using a timed sequential therapy approach where flavopiridol was given for the dual purpose of initial cytoreduction and enhancing cell cycle progression of the remaining leukemia cell cohort followed by cycle-dependent drugs 1-β-d-arabinofuranosylcytosine (ara-C) and mitoxantrone. Experimental Design: Flavopiridol was given by 1-hour infusion daily for 3 days beginning day 1 followed by 2 g/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone beginning day 9. In vivo correlates included pharmacokinetics, modulation of blast cycle regulators, and serum and marrow supernatant vascular endothelial growth factor levels. Results: Of 34 adults receiving induction therapy, 16 (47%) evinced direct leukemia cytotoxicity with ≥50% drop in peripheral blast counts and tumor lysis in 9 (26%). Four (12%) died during therapy (two fungal infections and two sudden death). Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia >40 days duration, and maximal tolerated dose was 50 mg/m2/d. Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia. Pharmacokinetics showed that a linear two-compartment model with first-order elimination provided the best fit of the observed concentration versus time data. Flavopiridol down-regulated one or more target proteins in marrow blasts in vivo. Vascular endothelial growth factor was detected in sera and marrow supernatant pretreatment, and sera obtained on day 3 inhibited bovine aortic endothelial cell proliferation by a mean of 32% (range, 10-80%). Conclusions: Our data suggest that flavopiridol is cytotoxic to leukemic cells and, when followed by ara-C and mitoxantrone, exerts biological and clinical effects in patients with relapsed and refractory acute leukemias. These findings warrant continuing development of flavopiridol at 50 mg/m2/d × 3 days in combination with cytotoxic and biological agents for acute leukemias.
Cochrane Systematic Reviews in Acupuncture: Methodological Diversity in Database Searching
Sood, Amit , Sood, Richa , Bauer, Brent A. , Ebbert, Jon O.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | August 30, 2005 | Volume: 11 | Issue: 4 | Pages: 719-722

10.1089/acm.2005.11.719 | PMID 16131298 Get It